Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2025-05-12 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-05-12 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding an update on a USFDA inspection at the company's manufacturing facility. It references Regulation 30 of SEBI Listing Regulations, which pertains to disclosure of material events. The document does not contain financial data, detailed reports, or management discussion. It is an announcement of an event (inspection result) rather than a full report or detailed filing. The length is only 1792 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-18 English
Updates
Regulatory Filings Classification · 100% confidence The document is a formal letter addressed to stock exchanges informing about a change in the email and website address of the company's Registrar and Share Transfer Agent (RTA). It does not contain any financial data, report, or detailed disclosures. The content is an announcement of a change in administrative contact details, which is a regulatory update but does not fit into categories like Annual Report, Earnings Release, or Management Reports. The document length is short (2048 characters), and it is clearly an informational notice. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-18 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. It is a compliance-related certificate from the Registrar and Share Transfer Agent confirming dematerialisation and securities status. The document is short (3504 characters) and serves as a regulatory confirmation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance and regulatory confirmations that do not fit other specific categories.
2025-04-08 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Emcure's European subsidiary Tillomed has acquired a strategic pharma portfolio from Manx. It contains details about the acquisition agreement, financial terms, and strategic significance. There are no financial statements, regulatory certifications, voting results, or management changes. The document is an announcement of a corporate transaction but not a merger filing or tender offer document. It is not a full financial report or earnings release. The content fits best under Capital/Financing Update (CAP) as it relates to a financing and acquisition activity announcement by the company.
2025-04-04 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new exclusive licensing partnership between Emcutix Biopharmaceuticals Limited (a subsidiary of Emcure Pharmaceuticals Limited) and WiQo for a derma-cosmetic product in India. It is addressed to stock exchanges and requests the press release to be taken on record. The content focuses on the business partnership, product details, and market potential, without any financial statements, regulatory filings, or detailed financial data. It is not an earnings release, annual report, or any regulatory filing. The document is clearly a press release announcing a business update, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-04-01 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.